Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George T Grossberg

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
Primary Care Companion to the Journal of Clinical Psychiatry|June 29, 2010
The art of sharing the diagnosis and management of Alzheimer's disease with patients and caregivers: recommendations of an expert consensus panelGeorge T Grossberg, Daniel D Christensen, Patrick A Griffith, et al.
Alzheimer'S Research & Therapy|March 11, 2015
Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patchJosé L Molinuevo, Lutz Frölich, George T Grossberg, et al.
Nature Reviews. Neurology|June 3, 2009
Management of agitation and aggression associated with Alzheimer diseaseClive G Ballard, Serge Gauthier, Jeffrey L Cummings, et al.
International Journal of General Medicine|January 7, 2022
Using Telemedicine to Assess and Manage Psychosis Among Outpatients with Neurodegenerative DiseaseCraig Chepke, Lynn W Shaughnessy, Stephen Brunton, et al.
Postgraduate Medicine|June 11, 2025
A US-based practitioner's guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer's dementia - recommendations of an expert, multispecialty advisory panelGeorge T Grossberg, Angela Sanford, C Brendan Montano, et al.
International Journal of Alzheimer'S Disease|August 28, 2010
Trial designs likely to meet valid long-term Alzheimer's disease progression effects: learning from the past, preparing for the futureAaron S Kemp, George T Grossberg, Steven J Romano, et al.
Neurodegenerative Disease Management|February 14, 2026
Brexpiprazole for treating agitation in different groups of people with Alzheimer's dementia: a plain language summaryJared Stroud, Jeffrey L Cummings, Sanjeda R Chumki, et al.
Journal of Alzheimer'S Disease Reports|February 3, 2021
Testing the Cognitive Reserve Index Questionnaire in an Alzheimer's Disease PopulationAsabe E Garba, George T Grossberg, Kimberly R Enard, et al.
Journal of Geriatric Psychiatry and Neurology|December 24, 2025
Efficacy of Brexpiprazole on Neuropsychiatric Symptoms and Impact on Caregivers: Pooled Neuropsychiatric Inventory (NPI) Analysis in Patients With Agitation Associated With Dementia due to Alzheimer's DiseaseGeorge T Grossberg, Marwan N Sabbagh, Sanjeda R Chumki, et al.
Clinical Drug Investigation|January 27, 2026
Efficacy of Brexpiprazole in Participants with Agitation Associated with Dementia Due to Alzheimer's Disease: Pooled Analysis of Randomized Controlled TrialsJeffrey L Cummings, Sanjeda R Chumki, Denise Chang, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
Primary Care Companion to the Journal of Clinical Psychiatry|June 29, 2010
The art of sharing the diagnosis and management of Alzheimer's disease with patients and caregivers: recommendations of an expert consensus panelGeorge T Grossberg, Daniel D Christensen, Patrick A Griffith, et al.
Alzheimer'S Research & Therapy|March 11, 2015
Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patchJosé L Molinuevo, Lutz Frölich, George T Grossberg, et al.
Nature Reviews. Neurology|June 3, 2009
Management of agitation and aggression associated with Alzheimer diseaseClive G Ballard, Serge Gauthier, Jeffrey L Cummings, et al.
International Journal of General Medicine|January 7, 2022
Using Telemedicine to Assess and Manage Psychosis Among Outpatients with Neurodegenerative DiseaseCraig Chepke, Lynn W Shaughnessy, Stephen Brunton, et al.
Postgraduate Medicine|June 11, 2025
A US-based practitioner's guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer's dementia - recommendations of an expert, multispecialty advisory panelGeorge T Grossberg, Angela Sanford, C Brendan Montano, et al.
International Journal of Alzheimer'S Disease|August 28, 2010
Trial designs likely to meet valid long-term Alzheimer's disease progression effects: learning from the past, preparing for the futureAaron S Kemp, George T Grossberg, Steven J Romano, et al.
Neurodegenerative Disease Management|February 14, 2026
Brexpiprazole for treating agitation in different groups of people with Alzheimer's dementia: a plain language summaryJared Stroud, Jeffrey L Cummings, Sanjeda R Chumki, et al.
Journal of Alzheimer'S Disease Reports|February 3, 2021
Testing the Cognitive Reserve Index Questionnaire in an Alzheimer's Disease PopulationAsabe E Garba, George T Grossberg, Kimberly R Enard, et al.
Journal of Geriatric Psychiatry and Neurology|December 24, 2025
Efficacy of Brexpiprazole on Neuropsychiatric Symptoms and Impact on Caregivers: Pooled Neuropsychiatric Inventory (NPI) Analysis in Patients With Agitation Associated With Dementia due to Alzheimer's DiseaseGeorge T Grossberg, Marwan N Sabbagh, Sanjeda R Chumki, et al.
Clinical Drug Investigation|January 27, 2026
Efficacy of Brexpiprazole in Participants with Agitation Associated with Dementia Due to Alzheimer's Disease: Pooled Analysis of Randomized Controlled TrialsJeffrey L Cummings, Sanjeda R Chumki, Denise Chang, et al.
Pageof 14